—Program Provides State-of-the-Art Quantitative Tissue Proteomics Technology to Research Pathologists Across North America & Europe —

NEW HAVEN, Conn., February 23, 2005— HistoRx, Inc. today announced plans to make its proprietary fluorescence-based AQUA™ tissue analysis platform available for licensing through a new program being offered to pathologists and scientists at universities and other noncommercial research institutions throughout North America and Europe. The Company will introduce HARP™ (HistoRx Academic Research Program) at the 94th Annual Meeting of the United States and Canadian Academy of Pathology Meeting taking place February 26—March 4, 2005 in San Antonio.

The HARP™ program provides access to high-throughput technology that enables pathology researchers interested in tissue proteomics and tissue biomarkers to, for the first time, quantify and localize proteins in specified subcellular compartments in tissue using a new fluorescent readout.

“HARP™ members can access cutting-edge quantitative pathology technology that vastly improves understanding of disease-related proteins and biomarkers in tissue,” said Robert A. Curtis, President & CEO of HistoRx. “By creating a program specifically geared to noncommercial researchers, we can ignite awareness of the AQUA™ System for digital quantitative pathology and fuel rapid advances in tissue proteomics as the technology evolves from a breakthrough new research tool for drug discovery and clinical development to a technology applied to clinical molecular diagnostic testing. Our HARP™ members will benefit from world-class technology advancements and harness the power of hundreds of other research pathologists to drive new discoveries in basic research and improve understanding of drug action.”

Academic and other not-for-profit research institutions are eligible to enroll in the HARP™ program, which involves purchasing HistoRx’s PM-2000™ Image Analyzer hardware along with corresponding AQUA™ Tissue Analysis software and X-Tile™ advanced statistical analysis package. Program membership includes participation in the HARP™ User Group, a members’ forum encompassing research pathologists around the world actively engaged in:

—Sharing AQUA™ analysis results, including newly identified biomarkers and protein expression patterns in disease-related tissue

—Meeting periodically to discuss new scientific information, stimulate research collaborations among institutions, and produce publications involving various applications of the AQUA™ System technology.

About the AQUA™ System
HistoRx’s AQUA™ System allows users to accurately measure the location and quantity of critical proteins within the subcompartments of cells in a tissue sample while maintaining their relative spatial relationships. These breakthrough capabilities position pathologists to address key challenges and opportunities in molecular medicine by enabling:

—highly accurate, site-specific measurement of protein expression that is not limited to traditional cell compartments and morphologic classifications

—identification of biologically significant diagnostic results that are undetectable using conventional pathological analysis

—standardization of analysis and scoring

ABOUT HISTORX, INC.
HistoRx, Inc. is developing a new generation of advanced quantitative diagnostic products for the research and clinical pathology markets based on the company’s proprietary integrated tissue analysis platform, AQUA™. Initially, HistoRx is providing contract services to the pharmaceutical and biotechnology industries while selectively licensing its technologies to leading academic and not-for-profit research institutions through the HARP™ program. Simultaneously, the company is advancing development of proprietary fluorescence-based molecular diagnostic tests for use with its AQUA™ platform that will enable biologically based selection of patients who are most likely to benefit from specific therapies. HistoRx is based in New Haven, Conn. www.historx.com